Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript
Dentsply Sirona (XRAY) reported Q2 2026 revenue of $898 million, down 4.1% reported (6.3% constant currency). Adjusted EPS was $0.52. Tariff refunds were $44 million, aiding operating cash flow of $99 million. Full-year revenue guidance was maintained at $3.5 to $3.6 billion and adjusted EPS at $1.40 to $1.50.
How this was made
The 30-second read
Why it matters
The key tradable elements are the reported Q2 financials, the maintained FY26 revenue and adjusted EPS guidance (with explicit exclusions for tariff refunds and incremental tariffs), and the Q3 outlook for sequential revenue decline and lower earnings versus Q2 excluding refunds.
Market read
Traders can update XRAY positioning based on the explicit Q3 earnings outlook (below Q2 excluding tariff refunds) and the maintained FY26 guidance with tariff-refund normalization.
What to watch
The call highlights private-equity-owned dealer inventory reductions (12 weeks to ~8) and DS Core platform rollouts, which could affect near-term sell-in timing and longer-term digital workflow adoption.
Background
Dentsply Sirona is about 6 months into a 24-month restructuring program focused on commercial re-alignment and distribution expansion, with Byte being wound down.
Ticker impact
Dentsply Sirona reported Q2 revenue of $898M, adjusted EPS of $0.52, and maintained FY26 guidance while detailing tariff refunds and Byte wind-down impacts.
Near-term volatility likely around segment margin and demand commentary, with upside limited by continued revenue decline expectations into Q3.
The article provides concrete earnings and guidance numbers plus specific drivers (tariff refunds, dealer inventory reductions, Byte wind-down) and a Q3 outlook that earnings are below Q2 excluding refunds.
Market effects
Dental equipment and consumables peers may face read-across on aligner wind-down (Byte) and inventory digestion by distributors in EMEA.
EMEA demand softness for capital equipment and lower sell-in due to dealer inventory reductions could pressure regional dental medtech demand expectations.
Tariff refund accounting and dealer inventory normalization are company-specific, but they can influence sector sentiment on working-capital and policy risk.
Counterpoint
Tariff refunds and working-capital improvements may overstate underlying demand strength, so investors could refocus on the underlying revenue declines excluding one-offs.
Key entities
- companyDentsply Sirona
XRAY, reported Q2 2026 results and maintained FY26 guidance while attributing declines to Byte wind-down and EMEA demand softness.
- executiveDaniel T. Scavilla
CEO who emphasized customer re-engagement and turnaround execution during the restructuring program.
- executiveJohn C. Fortson
CFO who discussed EMEA demand softening and sell-in reductions tied to distributor inventory levels.
- business unitByte
Direct-to-consumer clear aligner business being wound down, cited as a driver of OIS decline.
- platformDS Core
Cloud-based digital platform referenced as being implemented by European dental support organizations.
